ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "infliximab"

  • Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting

    Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway

    Guro Løvik Goll1,2, Inge C Olsen3, Kristin K Jorgensen4, Merete Lorentzen5, Nils Bolstad6, Espen A. Haavardsholm7, Knut EA Lundin8, Cato Mork9, Jorgen Jahnsen4, Tore K Kvien3 and the NOR-SWITCH study group, 1Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway, 8Dept of gastroenterology, Rikshospitalet, Oslo, Norway, 9Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

      Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of  spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA),  Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting

    Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice

    L Tweehuysen1, B.J.F. van den Bemt2, I.L. van Ingen3, A.J.L. de Jong4, W.H. van der Laan5, F.H.J. van den Hoogen5 and A.A. den Broeder5, 1Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 2Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 3Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, 4Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, 5Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose:  Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
  • Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting

    Strategies for Biological Drug Quantification in Biological Drug Immune Responses

    Michael Kruse Meyer1,2, Marlene Andersen1,3, Troels Vindbæk Stausbo4, Tue Bjerg Bennike4,5, Grethe Neumann Andersen1,6 and Allan Stensballe3,4, 1Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, 2Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, 3Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, 4Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, 5Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, 6Center for Clinical Science, Aalborg University, Hjørring, Denmark

    Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
  • Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting

    Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

    Theodora Bejan-Angoulvant1, David Ternant2, Fadela Daoued3, Frédéric Medina3, Louis Bernard4, Saloua Mammou3, Gilles Paintaud2 and Denis Mulleman5, 1Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, 2Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, 3Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, 4Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, 5Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France

    Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
  • Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting

    Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice

    Qi Quan Huang1, Robert Birkett1, Elyssa L Roberts2 and Richard M. Pope3, 1Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, 2northwestern University, Chicago, IL, 3Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…
  • Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting

    Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases

    M. Victoria Hernández1, Marina Mesquida2, Victor Llorens2, Maite Sainz de la Maza2, Gerard Espinosa3, Ricardo Blanco4, Vanesa Calvo4, Olga Maiz5, Ana Blanco6, Juan Ramon De Dios7, Pilar Ahijado-Guzman8, Enrique Judez9, Patricia Tejón10, M Soledad Peña11, Raimon Sanmarti1 and Alfredo Adan12, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, 3Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, 4Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, 6Ophthalmology Department. Donostia University Hospital, Donostia, Spain, 7Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, 8Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, 9Rheumatology Department. Hospital de Albacete, Albacete, Spain, 10Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, 11Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, 12Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain

    Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
  • Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting

    Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab

    Dalton Sholter1, Proton Rahman2, Maqbool Sheriff3, Michel Zummer4, Suneil Kapur5, Philip Baer6, Michael Starr7, John Kelsall8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Brendan Osborne11, Karina Maslova12, Cathy Tkaczyk11, Francois Nantel13 and Allen J Lehman12, 1University of Alberta, Edmonton, AB, Canada, 2Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 4Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 5University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, 6Independent Rheumatology Practice, Scarborough, ON, Canada, 7Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, 8Rheumatology, University of British Columbia, Vancouver, BC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 1319 Green belt Dr, Janssen Inc., Toronto, ON, Canada

    Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
  • Abstract Number: 2866 • 2015 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period

    Proton Rahman1, Michel Zummer2, William G Bensen3, Isabelle Fortin4, Dalton Sholter5, Milton F. Baker6, Regan Arendse7, Eliofotisti Psaradellis8, Emmanouil Rampakakis9, Francois Nantel10, Allen J Lehman10, Cathy Tkaczyk11, Karina Maslova10 and Brendan Osborne11, 1Medicine, Memorial University, St John's, NF, Canada, 2Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 4Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 5Rheumatology Associates, Edmonton, AB, Canada, 6VIHA, Victoria, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The efficacy and tolerability of golimumab (GLM) in patients with psoriatic arthritis (PsA) has been demonstrated in several controlled clinical trials. Longitudinal observational studies…
  • Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting

    What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry

    Rafat Faraawi1, Raman Joshi2, William G Bensen3, Denis Choquette4, Wojciech Olsynzynski5, Regan Arendse5, Maqbool Sheriff6, Proton Rahman7, Emmanouil Rampakakis8, Eliofotisti Psaradellis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11, Cathy Tkaczyk11 and Brendan Osborne11, 1McMaster University, Hamilton, ON, Canada, 2William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 4Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 5University of Saskatchewan, Saskatoon, ON, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7Medicine, Memorial University, St John's, NF, Canada, 8JSS Medical Research, St-Laurent, QC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…
  • Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting

    Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids

    Gülsah Akdemir1, Arie E. van der Bijl2, Badelog J.E. de Lange-Brokaar3, T. W. J. Huizinga1, Cornelia F. Allaart1 and Margreet Kloppenburg3, 1Rheumatology, LUMC, Leiden, Netherlands, 2Isala Klinieken, Zwolle, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…
  • Abstract Number: 1273 • 2015 ACR/ARHP Annual Meeting

    Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea

    Seoyoung C. Kim1, Nam-Kyong Choi2, Joongyub Lee2, Kyoung-Eun Kwon3, Wesley Eddings4, Yoon-Kyoung Sung5, Hong Ji Song6, Aaron K. Kesselheim4 and Daniel H. Solomon7, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Seoul National University Hospital, Seoul, South Korea, 3Seoul National University College of Medicine, Seoul, South Korea, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 5Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea, 6Hallym University Sacred Heart Hospital, Anyang, South Korea, 7Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Development of tumor necrosis factor (TNF) inhibitors has been a major advance in treatment of systemic inflammatory diseases, such as rheumatoid arthritis. While TNF…
  • Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting

    An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry

    Jeffrey R. Curtis1, Ying Shan2, Joel M. Kremer3, Katherine Saunders4, Dennis Parenti5 and Shelly Kafka5, 1University of Alabama at Birmingham, Birmingham, AL, 2UMass Memorial Medical Center, Worcester, MA, 3Albany Medical College, Albany, NY, 4Corrona LLC, Atlanta, GA, 5Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
  • Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting

    Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab

    Ignacio Ortea1, Bernd Roschitzki2, Eva Tomero3, Juan G. Ovalles-Bonilla4, Javier Lopez-Longo5, Inmaculada de la Torre5, Isidoro Gonzalez-Alvaro6, Juan J Gomez-Reino7 and Antonio Gonzalez8, 1Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, 2Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, 3Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 5Gregorio Marañon Hospital, Madrid, Spain, 6Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, 7Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 8Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain

    Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
  • Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting

    Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease

    Shunsei Hirohata1, Hirotoshi Kikuchi2, Tetsuji Sawada3, Hiroko Nagafuchi4, Msataka Kuwana5, Mitsuhiro Takeno6 and Yoshiaki Ishigatsubo7, 1Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, 4Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 5Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 6Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, 7Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan

    Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
  • Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting

    Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada

    Boulos Haraoui1, Maqbool Sheriff2, Majed Khraishi3, Michael Starr4, John Kelsall5, Milton Baker6, Regan Arendse7, Sanjay Dixit8, William Bensen9, Philip Baer10, Rafat Faraawi8, Emmanouil Rampakakis11, John S. Sampalis11, Susan Otawa12, Allen J Lehman12, Francois Nantel13 and May Shawi13, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Montreal General Hospital, Montreal, QC, Canada, 5The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 6University of Victoria, Victoria, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8McMaster University, Hamilton, ON, Canada, 9Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 10Private Practice, Scarborough, ON, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada, 13Janssen Inc., Toronto, ON, Canada

    Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies